All News

To ease concerns from hesitant patients wary of the coronavirus disease 2019 (COVID-19) pandemic, physicians have implemented temperature checks and comprehensive symptom screening, as well as telehealth offerings to provide timely and effective care, said Brian LaMoreaux, MD, medical director of Horizon Therapeutics.

Vibhas Ratanjee is a senior practice expert with Gallup, based in Gallup's Irvine, California office. Vibhas is a well-known speaker and author and has contributed several articles on leadership and organizational development as well as how new technology will alter the future of work and the customer experience. His writing has featured in several global publications, including the Gallup Business Journal and the Harvard Business Review. Vibhas specializes in organizational development, culture change, and executive-level engagement strategies, including strengths-based leadership and succession management. Vibhas is also an executive coach and a leadership consultant to senior executives and CEOs. Vibhas works extensively in the health care and financial services sector.

This week, the top managed care news included Oncology Care Model timelines being extended due to COVID-19; shifting racial disparities in avoidable hospitalizations; nonprofit hospitals did not direct Medicaid expansion savings into communities.

Hydroxychloroquine (HCQ) does not prevent coronavirus disease 2019 (COVID-19), according to a new study, and The Lancet retracted a previous paper examining the drug's safety; voters are mainly split along party lines when it comes to in-person voting in a pandemic; ownership of a handgun is associated with a significantly greater risk of suicide by firearm.

Researchers created a test to determine which children with Carbamoyl-Phosphate Synthetase 2, Aspartate Transcarbamylase, And Dihydroorotase (CAD) gene deficiency will benefit from receiving a nutritional supplement previously deemed effective in children with the condition, according to a study published in Genetics in Medicine.

Based on findings of a study conducted by the Michael J. Fox Foundation for Parkinson Research, the individual annual economic burden for a patient with Parkinson disease amounted to $52,000 in 2017, with nonacute institutional care, inpatient hospitalization, and outpatient care indicated as the largest drivers of cost among differing coverage plans.

Bristol Myers Squibb announced the commercial launch of Zeposia (ozanimod) for relapsing multiple sclerosis (RMS). The oral treatment is the first and only approved sphingosine-1-phosphate receptor modulator with no genetic test or first dose observation at initiation.

Research has established an association between social risk factors and child health outcomes, while professional medical organizations have endorsed screening for such factors in clinical settings. Providing an in-person patient navigator to address family social needs leads to a decrease in child health care utilization, according to a study published in JAMA Network Open.

Brand Logo

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo
Alt TextAlt Text